Streetbeat News

NMTC

NeuroOne Medical Technologies Corporation

https://n1mtc.com

Industry

Medical - Devices

NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.

Open

0.78

Mkt cap

22M

Volume

342K

High

0.78

P/E Ratio

-1.48

52-wk high

2.00

Low

0.68

Div yield

N/A

52-wk low

0.60

NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) will present at the Virtual Investor Summit Microcap Event on November 21st, 2024. The company will also be available for 1-on-1 meetings.

Portfolio Pulse from

November 13, 2024 | 2:45 pm

NeuroOne Medical Technologies Corporation has expanded its distribution agreement with Zimmer Biomet, granting Zimmer Biomet exclusive rights to distribute NeuroOne's OneRF Ablation System in the U.S. and certain international markets. NeuroOne will receive a $3 million upfront payment, and the agreement is expected to enhance the company's sales revenue and profitability.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 8:17 pm

NeuroOne Medical Technologies Corporation announced a successful breakthrough case using their OneRF Ablation System at University Hospitals in Cleveland. The procedure involved 44 ablations in one patient, who is now reportedly seizure-free with improved mood and memory.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 1:28 pm

NeuroOne Medical Technologies shares are trading lower after the company announced that a hospital used the OneRF Ablation System.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 7:00 pm

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced the successful completion of the first human ablations using its OneRF Ablation System. The procedure was performed at a patient's bedside, saving time and costs associated with the operating room.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:15 pm

The Centers for Medicare and Medicaid Services (CMS) has granted approval for NeuroOne's ICD-10 procedure code for sEEG RF Ablation. This code, effective from October 1, 2024, positions NeuroOne's OneRF™ Ablation System for broader adoption and awareness in the healthcare system.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 1:31 pm

NeuroOne Medical Technologies Corp has filed for a mixed shelf offering of up to $150 million. This move allows the company to issue various types of securities, including common stock, preferred stock, debt securities, and warrants, over time.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 8:22 pm

NeuroOne Medical Technologies (NMTC) reported Q2 2024 earnings with a GAAP EPS of $(0.11), missing the $(0.08) estimate by 37.5%. Year-over-year, the company saw a 10% increase in losses but a 195.38% increase in sales, reaching $1.38M up from $466.18K.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:06 pm

NeuroOne announced the first implant of its OneRF Ablation Electrodes, marking a significant milestone. This FDA-cleared system is the first thin-film, sEEG-guided RF system capable of recording electrical activity and ablating nervous tissue, featuring temperature control.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 3:31 pm

In Monday's intraday session, several healthcare stocks experienced significant movements. Regencell Bioscience led the gainers with a 130.9% increase, while Lantern Pharma topped the losers with a 22.8% decline. The movements reflect varying market capitalizations and investor reactions to company-specific news or broader sector trends.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.